#Sweden #Lund #Hansa Biopharma #imlifidase #Guillain-Barré Syndrome

Hansa Biopharma's Breakthrough Results in 15-HMedIdeS-09 Phase 2 Study

Hansa Biopharma has recently announced positive results from its 15-HMedIdeS-09 Phase 2 clinical trial that evaluates imlifidase, an innovative IgG cleaving enzyme, for patients suffering from Guillain-Barré Syndrome (GBS). This rare condition, characterized by rapid onset muscle weakness, represents a significant unmet medical need, and the findings could pave the way for new treatment options.

The study involved a single arm, where 30 adults diagnosed with severe GBS were treated with imlifidase alongside intravenous immunoglobulin (IVIg). Results showed that patients receiving this combination experienced rapid improvement in functional status. In fact, the time required for these patients to regain the ability to walk independently was reduced significantly—by as much as six weeks compared to standard treatments, such as IVIg alone, as evidenced by statistical analyses.

One notable result is that 37% of patients reported the ability to walk independently within just one week after receiving treatment with imlifidase. Moreover, by the end of the eighth week, 67% were able to walk unaided, while 40.7% regained the ability to run. The data also highlighted a median time of just 16 days for patients to reach a key improvement on the Guillain-Barré Syndrome Disability Scale (GBS DS).

Chief R&D Officer Hitto Kaufmann commented on the importance of these findings, emphasizing that imlifidase can quickly and effectively clear IgG antibodies, addressing the underlying causes of nerve damage associated with GBS. This rapid action could meaningfully change the treatment landscape for patients grappling with severe forms of GBS, potentially reducing hospitalization times and facilitating faster recovery to independent living.

In a comparative analysis with the International Guillain-Barré Syndrome Outcome Study (IGOS), results from the 15-HMedIdeS-09 study demonstrated that patients treated with imlifidase combined with IVIg showed statistically significant improvements across multiple clinical measures over various time points. The similarities in the progression of the two patient groups—those taking imlifidase and those undergoing traditional treatments—underscore the potential benefits of introducing imlifidase into standard care protocols for GBS.

The study's findings are crucial, given that GBS affects approximately 1-2 in every 100,000 individuals annually, leading to symptoms ranging from mild weakness to severe paralysis, often requiring mechanical ventilation for life-saving treatment. With many patients struggling with long-term disability, the positive impact of imlifidase could potentially alter the prognosis and quality of life for future patients.

Professor Shahram Attarian, one of the study's principal investigators, noted that these early improvements in mobility are significant milestones in a patient's recovery journey, reflecting their return to a better quality of life. The study provides a compelling case for considering imlifidase as a promising treatment alternative in conjunction with traditional immunoglobulin therapy.

As part of its commitment to combating autoimmune diseases, Hansa Biopharma is continuing its research and development efforts around imlifidase and other related therapies. The organization aims to address the pressing needs in the realm of autoimmune conditions, particularly where conventional treatments fall short.

Overall, the promising results from the 15-HMedIdeS-09 Phase 2 study represent a pivotal moment for Hansa Biopharma and the Guillain-Barré Syndrome community. The findings emphasize the urgent need for alternative treatment strategies, potentially offering hope to patients suffering from this debilitating condition.

Hansa plans to share more detailed data, along with a comparison to real-world data sources, during an upcoming conference call. For professionals and interested parties, there is an increasing amount of optimism surrounding the role imlifidase may play in the future of GBS treatment.